Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 9/20 | 0.75 |
| ▸ | NOD2 | Q9HC29 | 9/20 | 0.75 |
| ▸ | WEE1 | P30291 | 7/20 | 0.75 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.75 |
| ▸ | SRC | P12931 | 6/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.75 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.75 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.75 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.75 |
| ▸ | JAK2 | O60674 | 1/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.75 |
| ▸ | PAK4 | O96013 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514068 | 0.93 | RIPK2 (0.65) | RIPK2NOD2WEE1ACVR1SRC | |
| SCHEMBL14594125 | 0.93 | RIPK2 (0.68) | RIPK2NOD2WEE1ACVR1SRC | |
| SCHEMBL5520692 | 0.87 | RIPK2 (0.62) | RIPK2NOD2WEE1ACVR1SRC | |
| SCHEMBL5520426 | 0.87 | RIPK2 (0.73) | RIPK2NOD2WEE1ACVR1SRC | |
| SCHEMBL14594178 | 0.86 | RIPK2 (0.59) | RIPK2NOD2WEE1ACVR1SRC | |
| Pd-0166285 SCHEMBL133914 | 0.85 | FGFR1 (1.00) | RIPK2NOD2WEE1ACVR1SRC | |
| Pd-0166285 SCHEMBL30250248 | 0.85 | FGFR1 (1.00) | RIPK2NOD2WEE1ACVR1SRC | |
| Pd-0166285 SCHEMBL15106017 | 0.85 | FGFR1 (0.98) | RIPK2NOD2WEE1ACVR1SRC | |
| Pd-0166285 SCHEMBL30276696 | 0.85 | FGFR1 (0.98) | RIPK2NOD2WEE1ACVR1SRC | |
| SCHEMBL7692818 | 0.85 | SRC (0.75) | RIPK2NOD2WEE1ACVR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | claimed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | claimed |
| WO-2002076954-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-03 | — | — | WO | claimed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | claimed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| WO-2002076954-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | RIPK2 431/4885NOD2 3635/4885WEE1 63/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | RIPK2 456/4885NOD2 3496/4885WEE1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.